Here are 15 key notes on orthopedic and spine device companies from the past week.
New Brunswick, N.J.-based Johnson & Johnson launched a new program to avoid executive burnout focused on boosting the health and personal care of senior executives.
Research and Markets launched the Johnson & Johnson market research portal, which will offer access to Johnson & Johnson company research.
Cambridge, Mass.-based InVivo Therapeutics enrolled another patient in its INSPIRE study of the Neuro-Spinal Scaffold for spinal cord injury, and the patient is the seventh out of 11 patients who reported an AIS grade improvement at the one-month follow-up after the procedure.
Bordeaux, France-based Implanet's 2016 revenue grew 18 percent over 2015.
Walnut Creek, Calif.-based Providence Medical Technology earned FDA clearance for its CAVUX Cervical Cage-L System and ALLY Facet Screws.
San Diego-based NuVasive announced FDA clearance of its CoRoent Small Interbody System for up to four contiguous levels.
Toronto Western Hospital represents the first Canadian site for Cambridge, Mass.-based InVivo Therapeutics' cervical spinal cord injury study.
New Brunswick, N.J.-based DePuy Synthes launched the ATTUNE Revision Fixed Bearing Tibial Base and the 14mm by 50 mm Cemented Stem.
A study found that DePuy Synthes' ATTUNE Knee's estimated cumulative percent revision was 1.39 percent at three years, translating to a 98.61 percent survivorship rate.
DePuy Synthes Mitek Sports Medicine released a new suite of arthroscopic devices.
Aliso Viejo, Calif.-based OrthAlign announced the completion of the 60,000th joint arthroplasty case using the medical device company's technology.
Plainsboro, N.J.-based Integra LifeSciences announced full commercial availability of its Cadence Total Ankle system.
Integra LifeSciences' partnership with India-based Dr. Reddy's Laboratories will expand the device company's global market.
Canton, Mass.-based Organogenesis acquired Birmingham, Ala.-based NuTech Medical to tap in to the profitable orthopedic and spine tissue product market.
Boise, Idaho-based Burst Biologics will begin a study involving spinal fusion patients.